Telomir Pharmaceuticals, Inc.
TELO· Nasdaq
TELOTelomir Pharmaceuticals, Inc.
Filed Nov 12, 2024 · 10-Q · 43 days after period end · 0001493152-24-044749
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Income | -$5.99M | -$1.71M |
| EPS Diluted | -$0.20 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Telomir Pharmaceuticals, Inc. · CIK 1971532 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 12, 2024 · 43 d after period end
